Continued strong performance in Reproductive Medicine which exceeded sales of €1 billion for the first time Adstiladrin® (nadofaragene ...

In its first full year on the U.S. market, bladder cancer treatment Adstiladrin earned about $77 million. Elsewhere, Lilly ...

C. diff causes nearly 30,000 deaths each year in the US, says Ferring, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections.

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

Jean-Frédéric Paulsen, Chairman of the Board of Directors, said: "For Ferring, this was a year of both continuity and change as we drew on the company's strengths while evolving our approach to ...

adding that there were many kinds of unapproved and fake medications on the market. Dr Vishal Shah, Medical and Real-world Evidence Director at Project Family – Safe Birth said FERRING was ...

Operating expenses were carefully managed while prioritising investment in growth opportunities, such as Adstiladrin. This resulted in an overall cost reduction of -3% (at AER and CER). Consequently, ...